



June 15, 2009

Dear Passport Health Plan (PHP) Provider,

Our records indicate you have prescribed Treximet, Relpax, or agents in the Zomig family. Effective June 30, 2009, the following changes will be made to the preferred status of the Serotonin 5-HT<sub>1</sub> Receptor Agonists (Triptans), as approved by the PHP Pharmacy & Therapeutics Committee.

1. Sumatriptan (generic Imitrex) will be first line therapy.
2. Treximet will remain preferred but require step therapy with a trial of sumatriptan.
3. Zomig, Zomig ZMT and Relpax will be removed from the Preferred Drug List and require prior authorization.

Members currently receiving treatment with Zomig, Zomig ZMT and Relpax will be grandfathered for one year. After this time, continued treatment with a non-preferred agent will require prior authorization.

As always, we appreciate your continued support of Passport Health Plan. If you have questions or concerns about this formulary change, we value your feedback. Please contact our Pharmacy Department at (502) 585-8249.

Sincerely,

A handwritten signature in black ink, appearing to read "Thomas Kaye".

Thomas Kaye, RPh., MBA  
Senior Pharmacy Director

